on this page
Please note: You’ll get an immediate assessment when you request PBS authorities online.
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with daratumumab, elotuzumab, lenalidomide, pomalidomide and selinexor under the National Health Act 1953, section 100 for patients with multiple myeloma.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing daratumumab, elotuzumab, lenalidomide, pomalidomide and selinexor.
Section 100 - Highly Specialised Drugs
Elotuzumab, lenalidomide, pomalidomide and selinexor
These items are only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:
- an approved private hospital
- a public hospital.
These items aren’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.
Section 100 - Efficient Funding of Chemotherapy
Daratumumab
This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:
- an approved private hospital
- a public participating hospital.
This item isn’t PBS-subsidised for public hospital in-patients.
Authority applications
Lenalidomide
Applying for initial treatment as monotherapy for newly diagnosed disease
Applications for initial authority approval to prescribe PBS-subsidised lenalidomide as monotherapy to treat newly diagnosed multiple myeloma can be made in:
- real time using the Online PBS Authorities system
- writing and using HPOS Form upload
- writing and mailed to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed multiple myeloma newly diagnosed monotherapy - lenalidomide - initial authority application form
- relevant attachments.
Applying for initial treatment as dual therapy for newly diagnosed disease
Applications for initial authority approval to prescribe PBS-subsidised lenalidomide as dual therapy to treat newly diagnosed multiple myeloma can be made in:
- real time using the Online PBS Authorities system
- writing and using HPOS Form upload
- writing and mailed to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed multiple myeloma newly diagnosed dual therapy - lenalidomide - initial authority application form
- relevant attachments.
Applying for initial treatment as triple therapy for newly diagnosed disease
Applications for initial authority approval to prescribe PBS-subsidised lenalidomide as triple therapy to treat newly diagnosed multiple myeloma can be made in:
- real time using the Online PBS Authorities system
- writing and using HPOS Form upload
- writing and mailed to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed multiple myeloma newly diagnosed triple therapy - lenalidomide - initial authority application form
- relevant attachments.
Applying for initial treatment for progressive disease
Applications for initial authority approval to prescribe PBS-subsidised lenalidomide to treat progressive multiple myeloma can be made in:
- real time using the Online PBS Authorities system
- writing and using HPOS Form upload
- writing and mailed to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed multiple myeloma progressive disease - lenalidomide - initial authority application form
- relevant attachments.
Applying for continuing treatment for progressive disease
Applications for continuing authority approval to prescribe PBS-subsidised lenalidomide to treat multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for treatment as triple therapy for relapsed and/or refractory disease
Applications for authority approval to prescribe PBS-subsidised lenalidomide as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Pomalidomide
Applying for initial treatment as dual therapy
Applications for initial authority approval to prescribe PBS-subsided pomalidomide as dual therapy to treat multiple myeloma can be made in:
- real time using the Online PBS Authorities system
- writing and using HPOS Form upload
- writing and mailed to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed multiple myeloma dual therapy - pomalidomide - initial authority application form
- relevant attachments.
Applying for initial treatment as triple therapy
Applications for initial authority approval to prescribe PBS-subsidised pomalidomide as triple therapy to treat multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for continuing treatment as dual therapy
Applications for continuing authority approval to prescribe PBS-subsidised pomalidomide as dual therapy to treat multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for continuing treatment as triple therapy
Applications for continuing authority approval to prescribe PBS-subsidised pomalidomide as triple therapy to treat multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Elotuzumab
As of 1 December 2024, initial treatment with elotuzumab as triple therapy is no longer PBS-subsidised due to commercial reasons. Continuing treatment with elotuzumab as triple therapy remains on the PBS to ensure continuity of the treatment for existing patients.
Applying for continuing treatment as triple therapy
Applications for continuing authority approval to prescribe PBS-subsidised elotuzumab as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Selinexor
Applying for initial treatment as dual therapy
Applications for initial authority approval to prescribe PBS-subsidised selinexor as dual therapy to treat relapsed and/or refractory multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS authority approvals line.
Applying for continuing treatment as dual therapy
Applications for continuing authority approval to prescribe PBS-subsidised selinexor as dual therapy to treat relapsed and/or refractory multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS authority approvals line.
Applying for initial treatment as triple therapy
Applications for initial authority approval to prescribe PBS-subsidised selinexor as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS authority approvals line.
Applying for continuing treatment as triple therapy
Applications for continuing authority approval to prescribe PBS-subsidised selinexor as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS authority approvals line.
Daratumumab
Applying for initial treatment as triple therapy for untreated disease
Applications for initial authority approval to prescribe PBS-subsidised daratumumab as triple therapy for untreated multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for initial grandfather treatment as triple therapy for untreated disease
For patients who received non-PBS-subsidised daratumumab treatment before 1 November 2025 for untreated multiple myeloma, apply for initial grandfather authority approval either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for continuing treatment as triple therapy for untreated disease
Applications for continuing authority approval to prescribe PBS-subsidised daratumumab as triple therapy for untreated multiple myeloma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.
Call the PBS Authority Approvals enquiry line for more information on selinexor.